4//SEC Filing
O'Neill Vincent 4
Accession 0001104659-24-106060
CIK 0001720893other
Filed
Oct 2, 8:00 PM ET
Accepted
Oct 3, 9:53 PM ET
Size
7.5 KB
Accession
0001104659-24-106060
Insider Transaction Report
Form 4
O'Neill Vincent
Other
Transactions
- Award
Common Stock
2024-09-17+21,250→ 25,157 total - Sale
Common Stock
2024-10-03$0.55/sh−5,556$3,056→ 19,601 total
Footnotes (3)
- [F1]The Issuer previously granted the Reporting Person an award of restricted stock units that would vest based on the Issuer's satisfaction of certain performance objectives and subject to the Reporting Person's continued service with the Issuer through October 1, 2024 (the "PSUs"). On September 17, 2024, the Compensation Committee of the Issuer's Board of Directors determined that performance conditions with respect to 21,250 PSUs had been satisfied and 21,250 shares of common stock became issuable to the Reporting Person on October 1, 2024.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023.
- [F3]The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $0.5500 to $0.5501. The Reporting Person undertakes to provide upon request the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
Documents
Issuer
BioXcel Therapeutics, Inc.
CIK 0001720893
Entity typeother
Related Parties
1- filerCIK 0001672718
Filing Metadata
- Form type
- 4
- Filed
- Oct 2, 8:00 PM ET
- Accepted
- Oct 3, 9:53 PM ET
- Size
- 7.5 KB